Carboplatin

Where the papers sit

18 papers from the last 6 months study carboplatin directly · updated from PubMed 12 Oct 2026

• Multicancer Platinum Chemotherapy

  Paclitaxel-carboplatin remains a platform for neoadjuvant and first-line treatment across cervical, breast, head-and-neck, thyroid, and other cancers. The literature emphasizes survival and response outcomes, including real-world comparisons of anthracycline-containing versus anthracycline-free regimens in triple-negative breast cancer. Immunotherapy and targeted additions such as dostarlimab or cetuximab broaden the treatment question beyond chemotherapy alone. Microphysiological models offer a parallel route to predict therapy response rather than establish a shared clinical standard.

  6 papers · 33.3%

• Lung Cancer Immunotherapy

  Platinum-pemetrexed chemotherapy is increasingly paired with immune checkpoint or pathway-directed therapy in advanced and resectable NSCLC. Atezolizumab and serplulimab anchor perioperative approaches, while atezolizumab with or without bevacizumab is tested in metastatic disease. EGFR-mutated tumors drive amivantamab combinations and ivonescimab after disease progression. Progression-free and overall survival, safety, and biomarker-defined benefit remain the key tests.

  5 papers · 27.8%

• Platinum Sensitization in Cancer

  Platinum sensitivity in ovarian cancer is being linked to sphingolipid signaling, mitochondrial-immune states, and regulated cell death. SMS1 and SMS2 emerge as distinct determinants of chemotherapy response, while multi-omics seeks predictors in high-grade serous disease. Purine analogues and sonosensitizer strategies aim to amplify carboplatin-associated apoptosis or autophagy, but evidence remains largely preclinical. Targeted therapy in HER2-positive salivary duct carcinoma shows that durable responses may also depend on non-platinum biology.

  5 papers · 27.8%

• Others — Mechanisms and Drug Delivery

  NF-κB inhibition is implicated in carboplatin’s ability to alleviate astrocytic TDP-43 neurotoxicity. A separate computational study models carboplatin activation and DNA-base binding on magnesium oxide using a dicarboxylate ligand. The shared focus is mechanistic rather than clinical, spanning neuroprotection and drug delivery. No single biological direction or therapeutic application unites the cluster.

  2 papers · 11.1%